Extracellular cyclic cGMP as a biomarker for effect of treatment (cytotoxic drugs and radiation) on gynecologic cancers


Several recent studies of cervical cancer have shown that  the cGMP signal pathway is of crucial importance in development and progression of human cervical cancer. We have previously shown that patients with increasing urinary cGMP levels after treatment indicate relapse. Translation studies in vitro and in vivo may lead to improve the  treatment of gynecologic cancers.

Publications:

An experimental study of cancer cells from the cervix - Radiation sensitivity, effect development and cGMP levels". Master's thesis in Norwegian (2008).

Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome (2007)

Urinary levels of cyclic guanosine monophosphate (cGMP) in patients with cancer of the uterine cervix: a valuable prognostic factor of clinical outcome? (1998)



Members:

Georg Sager (Principal investigator)